natgillin/translations-raw huggingface dataset:
Lumark is not a medicine and it is not intended to be used on its own.
Kaj je radionuklidni predhodnik Lumark in za kaj ga uporabljamo Lumark ni zdravilo in se ga ne sme uporabljati samega.
Therefore, in case of an inadvertent administration of Lumark, the radiotoxicity for the patient must be reduced by immediate (i.e. within 1 hour) administration of preparations containing chelators like Ca-DTPA or Ca- EDTA in order to increase the elimination of the radionuclide from the body.
v roku ene ure) dajanjem pripravkov, ki vsebujejo kelatorje, kot sta Ca-DTPA ali Ca-EDTA, da se pospeši odstranjevanje radionuklidov iz telesa.
Lutetium (177Lu) decays by β--emission to stable Hafnium (177Hf), with the most abundant β- (79.3%) having a maximum energy of 0.497 MeV.
Z emisijo β-sevanja maksimalne energije 0,497 MeV z največjo količino β-sevanja (79,3 %) lutecij (177Lu) razpade v stabilni hafnij (177Hf).
NAME OF THE MEDICINAL PRODUCT Lumark 80 GBq/mL radiopharmaceutical precursor, solution
IME ZDRAVILA Lumark 80 GBq/ml radionuklidni predhodnik, raztopina
- Keep this leaflet.
da nehate dojiti.
The product should be aseptically withdrawn through the stopper using sterilized single use needle and syringe after disinfection of the stopper.
Po dezinfekciji zaporke je treba radionuklidni predhodnik aseptično odvzeti skozi zaporko z uporabo sterilizirane igle in brizge za enkratno uporabo.
Manufacturer I.D.B.
Izdelovalec I.D.B Holland B.V.
For more information, refer to the package leaflet of the particular medicine to be radiolabelled.
Za več informacij glejte navodilo za uporabo določenega zdravila, ki bo radioaktivno označevano.
Lumark is only to be used by specialists experienced with in vitro radiolabelling Posology
Radionuklidni predhodnik Lumark smejo uporabljati le zdravniki specialisti, ki imajo izkušnje na področju radioaktivnega označevanja in vitro.
Marketing Authorisation Holder I.D.B.
Imetnik dovoljenja za promet z zdravilom I.D.B Holland B.V.
If you are breast-feeding
Če dojite
A more detailed study of the biodistribution of Lutetium (177Lu) chloride in mice confirms the relatively high uptake in the liver, kidneys and bone marrow The results indicated that lutetium (177Lu) chloride is accumulated in the bone marrow and emphasizes the importance of all Lutetium (177Lu) to be peptide-bound at injection, as well as the in-vivo stability of the radionuclide-chelate-complex during therapy.
Rezultati so pokazali, da se lutecijev (177Lu) klorid kopiči v kostnem mozgu, in poudarili pomen vezave vseh oblik lutecija (177Lu) na peptid ob injiciranju, kot tudi stabilnost kompleksa radionuklida in kelata in vivo med zdravljenjem.
Please refer to the package leaflet of the medicine that is to be radiolabelled with Lumark.
Upoštevajte navodilo za uporabo zdravila, ki bo radiooznačeno z radionuklidnim predhodnikom Lumark.
Take special care with the medicine that is radiolabelled with Lumark: - If you are breast-feeding
Pri uporabi zdravila, označenega z radionuklidnim predhodnikom Lumark, bodite posebej previdni: - če dojite.
Skin and subcutaneous tissue disorders: very common: Alopecia
Zelo pogosti: alopecija
What you need to know before the medicine radiolabelled with Lumark is used 3.
Kaj morate vedeti, preden vam bodo dali zdravilo, radiooznačeno z zdravilom Lumark
4.4 Special warnings and precautions for use
4.4 Posebna opozorila in previdnostni ukrepi Presoja razmerja med tveganji in koristmi pri posameznem bolniku
For information concerning special warnings and precautions for use of 177Lu-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Za informacije, ki zadevajo posebna opozorila in previdnostne ukrepe za uporabo z lutecijem 177označenih zdravil, glejte povzetek glavnih značilnosti zdravila/navodilo za uporabo zdravila, ki bo radioaktivno označevano.
Effects on ability to drive or use machines following treatment by Lutetium (177Lu)-labelled medicinal products is specified in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Vplivi na sposobnost vožnje ali upravljanja s stroji po zdravljenju z zdravilom, označenim z lutecijem (177Lu), so podrobno opisani v povzetku glavnih značilnosti zdravila/navodilu za uporabo posameznega zdravila, ki bo radioaktivno označevano.
Storage must be in accordance with local regulations for radioactive substances 10.
Shranjujte v skladu z lokalnimi predpisi o radioaktivnih snoveh.
Each vial contains a volume varying from 0.1 to 5 mL corresponding to an activity ranging from 8 to 400 GBq at the ART.
Ena viala vsebuje prostornino, ki obsega od 0,1 do 5 ml raztopine, ki ustreza aktivnosti v obsegu od 8 do
Store in the original package to protect from radiation.
Shranjujte v originalni ovojnini za zaščito pred sevanjem.
Store in the original package in order to protect from radiation.
Shranjujte v originalni ovojnini za zagotovitev zaščite pred sevanjem.
Lumark is a radiopharmaceutical precursor.
4.1 Terapevtske indikacije Lumark je radionuklidni predhodnik.
Gastrointestinal disorders: very common: Nausea and vomiting
Zelo pogosti: navzea, bruhanje
• Reduction in blood cell counts (platelets, red or white blood cells)
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov): - zmanjšanje števila krvnih celic (krvnih ploščic, rdečih ali belih krvnih celic)
What Lumark contains - The active substance is Lutetium (177Lu) chloride.
Kaj vsebuje radionuklidni predhodnik Lumark - Zdravilna učinkovina je lutecijev (177Lu) klorid.
microgram of Lutetium.
Vsebuje zdravilno učinkovino lutecijev
For information on contraindications to particular Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, refer to the Summary of Product Characteristics/package leaflet of each particular medicinal product to be radiolabelled.
Za informacije o kontraindikacijah posameznih, z lutecijem (177Lu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radionuklidnim predhodnikom Lumark, glejte povzetek glavnih značilnosti zdravila/navodilo za uporabo posameznega zdravila, ki bo radioaktivno označevano.
Lumark 80 GBq/mL radiopharmaceutical precursor, solution Lutetium (177Lu) chloride
Lumark 80 GBq/ml radionuklidni predhodnik, raztopina lutecijev (177Lu) klorid
Ovaries
VIALA
Neoplasms benign, malignant and unspecified (including cysts and polyps): common: Refractory cytopenia with multilineage dysplasia (Myelodysplastic syndrome) (see section 4.4) uncommon: Acute myeloid leukaemia (see section 4.4)
Pogosti: refraktarna citopenija z displazijo več celičnih linij (mielodisplastični sindrom) (glejte poglavje 4.4)
Hormone release syndromes:
Bolezni prebavil:
The following preparations must be available in medical institutions, which use Lumark for radiolabelling of carrier molecules for therapeutic purposes: - Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or - Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
- Ca-DTPA (trinatrijev kalcijev dietilentriaminpentaacetat) ali - Ca-EDTA (kalcijev dinatrijev etilendiamintetraacetat)
Adverse reactions following the intravenous administration of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, will be dependent on the specific medicinal product being used.
Neželeni učinki, ki so posledica intravenskega dajanja zdravil, označenih z lutecijem (177Lu) in pripravljenih z radioaktivnim označevanjem z radionuklidnim predhodnikom Lumark, bodo odvisni od specifičnega zdravila, ki bo uporabljeno.
EXPIRY DATE EXP: {DD/MM/YYYY} BATCH NUMBER
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP: {DD/MM/LLLL}
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Lumark 80 GBq/mL radiopharmaceutical precursor, solution Lutetium (177Lu) chloride
IME ZDRAVILA IN POT(I) UPORABE Lumark 80 GBq/ml radionuklidni predhodnik, raztopina lutecijev (177Lu) klorid
Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been observed after treatment with Lutetium (177 Lu) peptide receptor radionuclide therapy for neuroendocrine tumours (see section 4.8).
Po radionuklidni terapiji z lutecijem (177 Lu) s peptidnimi receptorji za nevroendokrine tumorje so poročali o mielodisplastičnem sindromu (MDS) in akutni mieloični levkemiji (AML) (glejte poglavje 4.8).
It decays by emission of beta radiation of maximal 498 keV to 177Hf-Hafnium.
Lutecijev klorid razpade v hafnij (177Hf) z emisijo beta sevanja maksimalne energije 498 keV.
Cases of hepatotoxicity have been reported in the post-marketing setting and in the literature in patients with liver metastases undergoing treatment with 177Lu peptide receptor radionuclide therapy for neuroendocrine tumours.
Po prihodu zdravila na trg in v literaturi, pri bolnikih z metastazami jeter, ki prejemajo radionuklidno terapijo s peptidnimi receptorji (PRRT) za lutecij (177Lu) za zdravljenje nevroendokrinih tumorjev, so poročali o primerih hepatotoksičnosti.
For more information concerning the paediatric use of Lutetium (177Lu)-labelled medicinal products refer to the Summary of Products Characteristics/package leaflet of the the particular medicinal product to be radiolabelled.
Za več informacij v zvezi s pediatrično uporabo zdravil, označenih z lutecijem (177Lu), glejte povzetek glavnih značilnosti zdravila/navodilo za uporabo določenega zdravila, ki bo radioaktivno označevano.
The radiopharmaceutical precursor solution is packaged in colourless type I glass vial of 10 mL, closed with a bromobutylrubber stopper and aluminium overseal.
ki je zaprta z zaporko iz bromobutilne gume in z aluminijastim pokrovčkom.
No interaction studies of Lutetium (177Lu) with other medicinal products have been performed.
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Študij medsebojnega delovanja lutecija (177Lu) z drugimi zdravili niso izvedli.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER I.D.B.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Dry mouth has been reported among patients with prostate cancer receiving treatment with Lutetium (177Lu)
Pri bolnikih z metastatskim na kastracijo odpornim rakom prostate, ki so prejemali z lutecijem (177Lu)
The pharmacodynamic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakodinamične lastnosti z lutecijem (177Lu) označenega zdravila, pripravljenega z radioaktivnim označevanjem z radionuklidnim predhodnikom Lumark pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označevano.
Lumark is used for radiolabelling medicines, a technique in which medicines are tagged (radiolabelled) with a radioactive form of the element lutetium, known as lutetium (177Lu).
z radioaktivno obliko elementa lutecija, imenovanega lutecij (177Lu).
1 vial contains
radionuklidni predhodnik, raztopina 1 viala vsebuje
Destination:
Naslov za dostavo:
Extravasation: There have been reports of extravasation of Lutetium (177Lu) labelled ligands in the post-marketing setting.
V obdobju trženja zdravila so poročali o ekstravazaciji ligandov, označenih z lutecijem (177Lu).
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
The pharmacokinetic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
5.2 Farmakokinetične lastnosti Farmakokinetične lastnosti z lutecijem (177Lu) označenih zdravil, pripravljenih z radioaktivnim označevanjem z radionuklidnim predhodnikom Lumark pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označevano.
Anaemia, thrombocytopenia, leucopenia, lymphopenia, and less commonly neutropenia may occur during radioligand therapy with Lutetium (177Lu).
Mielosupresija Pri radioligandni terapiji z lutecijem (177Lu) se lahko pojavi anemija, trombocitopenija, levkopenija,
Testes
Odmerjanje
For information concerning interactions associated with the use of Lutetium (177Lu)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the radiolabelled medicinal product.
Za informacije o medsebojnem delovanju, povezanem z uporabo z lutecijem (177Lu) označenih zdravil, glejte povzetek glavnih značilnosti zdravila/navodilo za uporabo zdravila, ki bo radioaktivno označevano.
The presence of free Lutetium (177Lu) chloride in the body after an inadvertent administration of Lumark will lead to increased bone marrow toxicity and haematopoetic stem cell damage.
Prisotnost prostega lutecijevega (177Lu) klorida v telesu po nenamernem dajanju radionuklidnega predhodnika
PARTICULARS TO APPEAR ON THE OUTER PACKAGING PLASTIC JAR and LEAD CONTAINER
PLASTIČNI LONČEK in SVINČENI VSEBNIK
Radiopharmaceutical precursor, solution.
Shranjevanje radionuklidnega predhodnika Lumark 6.
EU/1/15/1013/001 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM
177Lu-Lutetium has a half-life of 6.647 days.
Lutecij 177Lu ima razpolovni čas
Product Characteristics of the medicinal product to be radiolabelled.
To je tehnika, pri kateri se zdravila označijo (radiooznačijo)
Clear, colourless solution.
limfopenija in, manj pogosto, nevtropenija.
• Mild temporary hair loss Common (may affect up to 1 in 10 people):
Neželeni učinki, o katerih so poročali pri bolnikih, pri katerih so zdravili nevroendokrine tumorje: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): - blaga, začasna izguba las
Educational material shall consist of information aiming to minimise adverse events and support effective use through adequate education about:
Izobraževalna gradiva morajo vsebovati informacije, namenjene minimizaciji neželenih dogodkov in bodo pripomogla k učinkoviti uporabi z ustreznim informiranjem o:
The Member States must ensure that the Marketing Authorisation Holder will provide healthcare professionals with educational materials for healthcare professionals and patients.
Države članice morajo zagotoviti, da bo imetnik dovoljenja za promet z zdravilom zdravnikom zagotovil izobraževalna gradiva za zdravnike in bolnike.
The educational materials are aimed at risk minimisation and will support safe and effective use of the product by the patient.
Namen izobraževalnih gradiv je minimizacija tveganja ter podpora varni in učinkoviti uporabi zdravila med bolniki.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE ADDRESSED TO THE MEMBER STATES
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH JE TREBA NASLOVITI NA DRŽAVE ČLANICE
a) The need for consistent and standard inhalation technique to ensure both optimal and consistent b) Special precaution with the insulin inhaler e) Magnitude of titration steps and resulting precautions f) The change in pulmonary function and the need for pulmonary function monitoring g) Smoking in relation to induced alteration in pharmacokinetics j) Recommendation for special populations; underlying lung diseases such as asthma and COPD, congestive heart failure, pregnancy, children and adolescent
e) velikosti titracijskih korakov in posledičnih previdnostnih ukrepih, f) spremembah delovanja pljuč in potrebi po nadziranju pljučnega delovanja, g) kajenju v zvezi s povzročenimi spremembami farmakokinetike,
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, ZDRAVILOM, KI JIH MORAJO IMPLEMENTIRATI DRŽAVE
Not known (frequency cannot be estimated from the available data)
Neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov):
July of each year until the results of the study in bone have been submitted.
Julij vsakega leta do predložitve rezultatov študije na kosteh.
DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION Date of first authorisation: 23 July 2007
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 23. julij 2007
• your kidneys do not work properly
• vaše ledvice ne delujejo ustrezno;
Dose level has no consistent effect on the volume of distribution in any of the studies.
Raven odmerka ni imela doslednega učinka na volumen porazdelitve pri nobeni izmed študij.
Administer the lowest dose possible for adequate imaging.
Dajte najnižji možni odmerek za ustrezno slikanje.
(See Annex I: Summary of Product Characteristics, section 4.2).
(glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2.)
The number of elderly patients in whom the pharmacokinetics were determined was limited (over 65 years, N=3).
Število starejših bolnikov, pri katerih so določali farmakokinetiko, je bilo omejeno (nad 65 let, n = 3).
System Organ Class (MedDRA)
Organski sistem (MedDRA)
If your kidneys are working normally it is unlikely you will have any problems.
Če vaše ledvice delujejo normalno, ni verjetno, da boste imeli kakršnekoli težave.
Date of latest renewal: 15 June 2012
Datum zadnjega podaljšanja: 15 junij 12
In this group of patients hypersensitivity reactions may be severe.
Pri tej skupini bolnikov so lahko preobčutljivostne reakcije hude.
The medicine should be used immediately.
Zdravilo je treba uporabiti takoj.
The doctor will decide how much Optimark is needed for your examination.
Zdravnik se bo odločil, koliko zdravila Optimark potrebujete za pregled.
15, rue des Vanesses 93420 Villepinte France
15, rue des Vanesses 93420 Villepinte Francija
No significant differences in pharmacokinetics based on gender were identified.
Pomembnih razlik pri farmakokinetiki na podlagi spola niso odkrili.
No functional impairment was observed.
Funkcionalnih okvar niso opazili.
The text shall be agreed by the CHMP and shall also contain the following key element:
Besedilo mora odobriti Odbor za zdravila za uporabo v humani medicini (CHMP) in mora vsebovati tudi naslednje ključne elemente:
This difference in enhancement pattern is useful in formulating a differential diagnosis based on lesion characterization and diagnostic confidence.
Ta razlika v vzorcih krepitve je uporabna pri formuliranju diferencialne diagnoze na podlagi karakterizacije lezij in diagnostični zanesljivosti.
• you are feeling thirsty and/or if you have only had small quantities or nothing to drink before the examination
• ste žejni in/ali ste pred pregledom pili zelo malo ali nič;
Effect of Gender:
Vpliv spola:
The repeat dose is not recommended in these populations.
Pri teh populacijah se ne priporoča dajanje ponavljajočih se odmerkov.
Osmolality (37°C): 1000 - 1200 mOsm/kg
Osmolalnost (37 °C): 1000-1200 mOsm/kg
The use of a contrast agent may therefore reduce the threshold for lesion detection and visualization.
Uporaba kontrastnega sredstva lahko torej zmanjša prag detekcije in vidnosti lezij.
The usual dose of 0.2 ml/kg body weight is the same in adults and children of 2 years and older.
Običajni odmerek 0,2 ml/kg telesne mase je enak za odrasle in za otroke, stare 2 leti ali več.
• you have heart disease
• imate srčno bolezen;
The dose used should also be recorded.
Zabeležite tudi uporabljeni odmerek.
Elderly (aged 65 years and above)
Starejši (stari 65 in več let)
Safety and efficacy have not been studied in this age group.
Varnosti in učinkovitosti v tej starostni skupini niso raziskovali.
Possible side effects are described in greater detail below.
Možni neželeni učinki so natančneje opisani spodaj.
• you are taking a special kind of antihypertensive medicine, i.e. a beta-blocker
• jemljete posebno vrsto zdravila proti zvišanem krvnem tlaku, tj. blokator beta;
The pharmacokinetics of gadoversetamide conforms to a two compartment open-model.
Porazdelitev Farmakokinetika gadoversetamida ustreza dvodelnemu odprtemu modelu.
Caution should be exercised in elderly patients.
Pri starejših bolnikih je potrebna previdnost.
Most of these reactions occur within half an hour after administering the contrast medium.
Večina teh reakcij se pojavi pol ure po injiciranju kontrastnega sredstva.
However, the administration of gadoversetamide does not cause a true decrease in serum calcium.
Vendar pa uporaba gadoversetamida ne povzroča resničnega znižanja kalcija v serumu.
Some of these lesions may be seen on unenhanced, non-contrast MRI.
Nekatere od teh lezij je mogoče videti na neokrepljeni, nekontrastni sliki MRI.
Before the examination, care must be taken that patients are sufficiently hydrated.
Pred slikanjem je treba paziti, da so bolniki dovolj hidrirani.
Up to 1 in 100 people may be affected.
Prizadene lahko do 1 od 100 bolnikov.
NSF may result in debilitating joint immobility, muscle weakness or may affect the normal working of internal organs which may potentially be life-threatening.
NSF lahko povzroči nepremičnost zaradi oslabitve sklepov, šibkost mišic ali vpliva na normalno delovanje notranjih organov, ki je lahko tudi smrtno nevarno.
If any of these apply to you, your doctor will decide whether the intended examination is possible or not.
Če za vas velja karkoli od naštetega, se bo zdravnik odločil, ali bo nameravani pregled opravil.
As with all other contrast media of the same class, late reactions may occur (after hours or days) in rare cases; however, none were reported in the completed clinical trials.
Kot pri drugih kontrastnih sredstvih istega razreda se lahko v redkih primerih pojavijo pozne reakcije (po več urah ali dneh); vendar pa pri končanih kliničnih preskušanjih o njih niso poročali.
There have been reports of nephrogenic systemic fibrosis (which causes hardening of the skin and may affect also soft tissue and internal organs).
Poročali so o nefrogeni sistemski fibrozi (ki povzroča odebelitev kože in lahko vpliva tudi na mehko tkivo in notranje organe).
Patients with cardiovascular disease
Bolniki s kardiovaskularnimi boleznimi
• you suffer from severe and/or acute kidney impairment, or
• imate hudo in/ali akutno ledvično okvaro ali
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katero koli zdravilo, tudi če ste ga dobili brez recepta.
If you are given more Optimark than you should have been If too much Optimark was injected it is unlikely that it will do you much harm, as much higher doses did not lead to any problems when some people received them.
Če ste vzeli večji odmerek zdravila Optimark, kot bi smeli Če so vam injicirali preveč zdravila Optimark, ni verjetno, da bo to povzročilo veliko težav, ker tudi veliko večji odmerki niso povzročali težav, ko so jih dali nekaterim osebam.
Read all of this leaflet carefully before you are being given this medicine because it contains important information for you.
Pred začetkom uporabe zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden uporabite to zdravilo.
In the absence of compatibility studies, Optimark should not be mixed with other medicinal products.
Zaradi pomanjkanja študij kompatibilnosti zdravila Optimark ne smemo mešati z drugimi zdravili.
Other medicines and Optimark
Druga zdravila in zdravilo Optimark
Discard any remaining solution after first use.
Preostalo raztopino zavrzite po prvi uporabi.
If you think you have been injected with too much Optimark, tell the doctor or nurse/technologist immediately.
Če mislite, da so vam injicirali preveč zdravila Optimark, takoj povejte zdravniku ali medicinski sestri/zdravstvenemu delavcu.
NSF is a disease involving thickening of the skin and connective tissues.
NSF je bolezen, pri kateri se odebelijo koža in vezivna tkiva.
From a microbiological point of view, the product should be used immediately.
Zaradi mikrobioloških razlogov je treba zdravilo porabiti takoj.